Stramsen Biotech's Negotiations with US Companies for Potential Acquisition and Reverse Merger

Stramsen Biotech, a leading plant-based biotech start-up, has been valued at $6.5 billion by a third-party valuation company, following a comprehensive evaluation of its management team, board of directors, scientists, assets, and commercial value of products.

The company's pipeline consists of 33 drug candidates and access to over 8,000 medicinal plants for future discoveries. Negotiations are underway for a possible reverse merger with US-based publicly traded companies, with hopes of becoming a public company in the near future.

Stramsen aims to capture 1-5% of the $1.7 trillion herbal medicine and therapeutics market within the next 5-15 years, projecting annual revenue of $17-85 billion in the next decade. The company plans to donate 100,000 shares of common stocks to eligible non-profit organizations supporting disabled military veterans, impoverished children in developing countries, and select individual military veterans.

Real the full press release here.